Regulation is not background noise. In European life sciences, it is part of the commercial model.
This section tracks the policy, access, compliance, and approval changes that shape adoption, timing, and strategic options.
Week of 29 June – 5 July 2026 The headline number this week was a deal figure. Naturally. Life sciences still loves a large cheque almost as much as it loves pretending “strategic optionality” is a strategy. But the real value this week was not created in the deal room. It was created at the…
Digital health companies love to talk about defensible technology. European health systems are much less romantic. They care whether the product gets used, fits the workflow, generates evidence, survives procurement and justifies reimbursement after the first enthusiasm fades. That is the content gap RankPilot was sensing, even if its prose arrived wearing SEO shoes two…
The EU AI Act has given life sciences companies more time on the most resource-intensive part of the regime. It has not permitted commercial teams to wait. On 29 June 2026, the Council of the European Union gave final approval to the Digital Omnibus on AI, part of the EU’s broader simplification agenda. The package…
The European MedTech launch model is not failing because clinicians stopped caring about innovation. It is failing because the buying system changed faster than the commercial operating model around it. When a European MedTech launch misses its number, the review usually lands on familiar explanations: pricing pressure, reimbursement delay, procurement friction, competitor response, or slower-than-expected…
Health Tech Pathways and the Bottleneck Upstream of EU MDR Health Tech Hub Copenhagen has launched an AI-guided platform to help startups navigate MDR. Useful. But the more interesting lesson is what the tool cannot solve: founders who have not yet decided what product they are actually regulating. Health Tech Pathways; HTH Copenhagen. The most…
Most medtech teams do not have a channel problem. They have an operating model problem. In Europe, where procurement, evidence, and market access vary wildly by country, omnichannel only works when commercial execution is designed as a system rather than a campaign. Most medtech teams do not have a channel problem Everyone says they are…
For years, European imaging AI founders have been trapped by Rule 11 of the MDR, which effectively pushed almost all diagnostic software into Class IIa or higher. However, the regulatory landscape shifted dramatically this week as the European Commission’s simplification proposal moved toward implementation, signaling a fundamental win for the digital health sector. 1. The…
Two watchdogs, one playbook. On 14 January 2026, the European Medicines Agency and the U.S. FDA jointly published “Guiding principles of good AI practice in drug development,” a concise set of 10 rules for using AI across the medicines lifecycle, from data collection and model building to post-market monitoring. It’s not a binding guidance, but…
Where the regulations help, the funding flows, and the pilots don’t take geological time If you ask ten founders where to launch a healthtech startup in Europe, eight will say Berlin, one will say London, and one will whisper Lisbon for “quality of life reasons”. They’re all partially right and all are missing the bigger…
If you work in HealthTech in Europe, you’ve probably noticed something strange. 2024 felt like the world was ending, yet the actual numbers say something very different.Capital didn’t disappear — it simply stopped tolerating nonsense. Now, in 2025, the money is flowing again, and aggressively so.But it’s flowing selectively. 2024: The Great Reality Filter Forget…